QuidelOrtho reported a 10.5% revenue decline to $620 million in Q1 2026, driven by a weak respiratory season and disruptions in China and the Middle East. The company posted a GAAP net loss of $92 million but highlighted growth in immunohematology and completed the LEX Diagnostics acquisition to boost molecular diagnostics. It lowered its full-year 2026 revenue and earnings guidance due to ongoing market challenges and pending China pricing guideline changes. QuidelOrtho remains focused on expanding margins and cash flow with new product launches in the U.S. and international markets.
The U.S. Bankruptcy Court for the Central District of California confirmed the Plan of Liquidation for Oceanwide Plaza LLC, enabling the $470 million sale of the stalled Downtown Los Angeles development to KPC Square, a joint venture between KPC Grou...
When Bitcoin blocks reach their 4 million weight unit limit, new transactions don't stop but enter a competitive fee auction in the mempool, where miners prioritize higher-fee transactions for confirmation. This dynamic means transactions with low fe...
Legrand SA has shown solid growth driven by strong demand in datacentres and effective operating leverage, despite facing unit margin pressures from raw material inflation and tariffs. The company expects organic growth of 4-7% and plans pricing acti...
FTX is set to distribute an additional $900 million to creditors, bringing total repayments to over $10 billion. This milestone marks significant progress in the bankruptcy process, offering hope to creditors who have been awaiting recovery of their ...
Zoom Communications has appointed Carlos Quaderi as Head of Asia Pacific (APAC), effective August 1, 2026, to lead its growth strategy across the region excluding Japan. Quaderi, with over 30 years of experience and previous leadership roles at Workd...
